Literature DB >> 33077666

Intrapulmonary Pharmacokinetics of Cefepime and Enmetazobactam in Healthy Volunteers: Towards New Treatments for Nosocomial Pneumonia.

Shampa Das1, Richard Fitzgerald2, Asad Ullah2, Marcin Bula2, Andrea M Collins2,3, Elena Mitsi3, Jesus Reine3, Helen Hill3, Jamie Rylance2,3, Daniela M Ferreira3, Karen Tripp2, Andrea Bertasini4, Samantha Franzoni4, Mameli Massimiliano4, Omar Lahlou5, Paola Motta5, Philip Barth5, Patrick Velicitat5, Philipp Knechtle5, William Hope6,2.   

Abstract

Cefepime-enmetazobactam is a novel β-lactam-β-lactamase inhibitor combination with broad-spectrum antimicrobial activity against a range of multidrug-resistant Enterobacteriaceae This agent is being developed for a range of serious hospital infections. An understanding of the extent of partitioning of β-lactam-β-lactamase inhibitor combinations into the human lung is required to better understand the potential role of cefepime-enmetazobactam for the treatment of nosocomial pneumonia. A total of 20 healthy volunteers were used to study the intrapulmonary pharmacokinetics of a regimen of 2 g cefepime-1 g enmetazobactam every 8 h intravenously (2 g/1 g q8h i.v.). Each volunteer contributed multiple plasma samples and a single epithelial lining fluid (ELF) sample, obtained by bronchoalveolar lavage. Concentrations of cefepime and enmetazobactam were quantified using liquid chromatography-tandem mass spectrometry. The pharmacokinetic data were modeled using a population methodology, and Monte Carlo simulations were performed to assess the attainment of pharmacodynamic targets defined in preclinical models. The concentration-time profiles of both agents in plasma and ELF were similar. The mean ± standard deviation percentage of partitioning of total drug concentrations of cefepime and enmetazobactam between plasma and ELF was 60.59% ± 28.62% and 53.03% ± 21.05%, respectively. Using pharmacodynamic targets for cefepime of greater than the MIC and free enmetazobactam concentrations of >2 mg/liter in ELF of 20% of the dosing interval, a regimen of cefepime-enmetazobactam of 2 g/0.5 g q8h i.v. infused over 2 h resulted in a probability of target attainment of ≥90% for Enterobacteriaceae with cefepime-enmetazobactam MICs of ≤8 mg/liter. This result provides a rationale to further consider cefepime-enmetazobactam for the treatment of nosocomial pneumonia caused by multidrug-resistant Enterobacteriaceae.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  ESBL; Monte Carlo simulation; beta-lactams; cefepime; enmetazobactam; pneumonia; population pharmacokinetics

Year:  2020        PMID: 33077666      PMCID: PMC7927813          DOI: 10.1128/AAC.01468-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  21 in total

1.  Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.

Authors:  Michael N Neely; Michael G van Guilder; Walter M Yamada; Alan Schumitzky; Roger W Jelliffe
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

2.  Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-β-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae.

Authors:  Adam Johnson; Laura McEntee; Nicola Farrington; Ruwanthi Kolamunnage-Dona; Samantha Franzoni; Alberto Vezzelli; Mameli Massimiliano; Philipp Knechtle; Adam Belley; Aaron Dane; George Drusano; Shampa Das; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

Review 3.  Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.

Authors:  Ryan G D'Angelo; Jennifer K Johnson; Jacqueline T Bork; Emily L Heil
Journal:  Expert Opin Pharmacother       Date:  2016-03-03       Impact factor: 3.889

Review 4.  Considerations for effect site pharmacokinetics to estimate drug exposure: concentrations of antibiotics in the lung.

Authors:  Keith A Rodvold; William W Hope; Sara E Boyd
Journal:  Curr Opin Pharmacol       Date:  2017-10-31       Impact factor: 5.547

5.  In vivo activities of simulated human doses of cefepime and cefepime-AAI101 against multidrug-resistant Gram-negative Enterobacteriaceae.

Authors:  Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2015-02-23       Impact factor: 5.191

6.  Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia.

Authors:  Emmanuel Boselli; Dominique Breilh; Frédéric Duflo; Marie-Claude Saux; Richard Debon; Dominique Chassard; Bernard Allaouchiche
Journal:  Crit Care Med       Date:  2003-08       Impact factor: 7.598

7.  Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.

Authors:  R E Kessler; M Bies; R E Buck; D R Chisholm; T A Pursiano; Y H Tsai; M Misiek; K E Price; F Leitner
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

8.  Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial.

Authors:  Patrick N A Harris; Paul A Tambyah; David C Lye; Yin Mo; Tau H Lee; Mesut Yilmaz; Thamer H Alenazi; Yaseen Arabi; Marco Falcone; Matteo Bassetti; Elda Righi; Benjamin A Rogers; Souha Kanj; Hasan Bhally; Jon Iredell; Marc Mendelson; Tom H Boyles; David Looke; Spiros Miyakis; Genevieve Walls; Mohammed Al Khamis; Ahmed Zikri; Amy Crowe; Paul Ingram; Nick Daneman; Paul Griffin; Eugene Athan; Penelope Lorenc; Peter Baker; Leah Roberts; Scott A Beatson; Anton Y Peleg; Tiffany Harris-Brown; David L Paterson
Journal:  JAMA       Date:  2018-09-11       Impact factor: 56.272

9.  Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia.

Authors:  Emmanuel Boselli; Dominique Breilh; Thomas Rimmelé; Jean-Charles Poupelin; Marie-Claude Saux; Dominique Chassard; Bernard Allaouchiche
Journal:  Intensive Care Med       Date:  2004-02-24       Impact factor: 17.440

Review 10.  Carbapenem-Sparing Strategies for ESBL Producers: When and How.

Authors:  Ilias Karaiskos; Helen Giamarellou
Journal:  Antibiotics (Basel)       Date:  2020-02-05
View more
  4 in total

Review 1.  OXA-48-Like β-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline.

Authors:  Sara E Boyd; Alison Holmes; Richard Peck; David M Livermore; William Hope
Journal:  Antimicrob Agents Chemother       Date:  2022-07-20       Impact factor: 5.938

2.  Penicillanic Acid Sulfones Inactivate the Extended-Spectrum β-Lactamase CTX-M-15 through Formation of a Serine-Lysine Cross-Link: an Alternative Mechanism of β-Lactamase Inhibition.

Authors:  Philip Hinchliffe; Catherine L Tooke; Christopher R Bethel; Benlian Wang; Christopher Arthur; Kate J Heesom; Stuart Shapiro; Daniela M Schlatzer; Krisztina M Papp-Wallace; Robert A Bonomo; James Spencer
Journal:  mBio       Date:  2022-05-25       Impact factor: 7.786

Review 3.  Penetration of Antibacterial Agents into Pulmonary Epithelial Lining Fluid: An Update.

Authors:  Emily N Drwiega; Keith A Rodvold
Journal:  Clin Pharmacokinet       Date:  2021-10-15       Impact factor: 6.447

Review 4.  Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol-An All-Inclusive Guide for Clinicians.

Authors:  Luigi Principe; Tommaso Lupia; Lilia Andriani; Floriana Campanile; Davide Carcione; Silvia Corcione; Francesco Giuseppe De Rosa; Roberto Luzzati; Giacomo Stroffolini; Marina Steyde; Giuliana Decorti; Stefano Di Bella
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.